12:00 AM
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Erbitux cetuximab: Phase III data

The open-label, international Phase III EXPAND trial in 904 patients with advanced gastric adenocarcinoma showed that first-line treatment with Erbitux plus cisplatin and Xeloda capecitabine missed the primary endpoint of PFS vs. cisplatin and Xeloda alone. Merck said the combination did not lead to...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >